PA Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

PA Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$263K	Buy	+2,300	New	+$248K	0.18%	145

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PA Capital's ALXN Position: Q3 2020 in Review

PA Capital increased its Alexion Pharmaceuticals (ALXN) stake by 34% in Q3 2020, buying an estimated $218K and bringing the position to 7,905 shares worth $905K. The position accounts for 0.64% of the portfolio, ranked #50.

PA Capital first reported a position in ALXN in Q1 2020 and has held it in 3 quarters since. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

PA Capital held 7,905 shares of Alexion Pharmaceuticals worth $905K as of Q3 2020.
PA Capital bought 2,022 Alexion Pharmaceuticals shares in Q3 2020, an estimated $218K.
Alexion Pharmaceuticals made up 0.64% of PA Capital's portfolio in Q3 2020, its #50 holding.
PA Capital first reported a position in Alexion Pharmaceuticals in Q1 2020 and has held it in 3 quarters since.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.